ANALYTICAL CHEMISTRY OF CHEMICALS AND PHARMACEUTICALS

获得性免疫缺陷综合征(AIDS)与 美国国立卫生研究院微生物学与传染病项目 过敏症和传染病组织积极参与各项计划，以： 开展传染病过程的基础调查，以及 发现治疗这些疾病的新的治疗方法 国家合作药物发现小组机制与筛选 程序。这些疗法针对的是各种传染性疾病。 疾病包括由艾滋病毒、巨细胞病毒、疱疹引起的疾病 单纯性肺炎、肺孢子虫肺炎、白色念珠菌、禽分枝杆菌 NIAID资助的药物发现中的一些，但不是全部 机制有能力和能力执行所需的 研究将具有预测活性的化学物质转化为 将体外试验系统或动物模型制成药物剂型 以足够的规模制造，以允许I期和II期临床 对物质的评价。这一倡议提供了分析 化学/质量控制能力，以验证身份和评估 在活体动物体内评估前的化学物质的纯度 模型、毒理学研究、药物剂型和临床 审判。此外，承包商还将评估其溶解性和 这些试剂的稳定性和推荐程序适用于 在体内疗效评价模型中对这些化合物的处理 和毒性。分配系数、pKa‘s和Ph的测定 与稳定性对比，将被用来获得初步的 关于一种可能预测生物行为的新化合物的信息。 承包商还将分析最终的剂型并评估其 随着时间的推移保持稳定。血液和血液中药物的评估方法和 尿液也将被开发出来。

The Division of Acquired Immune Deficiency Syndrome (AIDS) and the Microbiology and Infectious Disease Program of the National Institute of Allergy and Infectious Diseases are actively engaged in programs to: carry out basic investigations of the infectious disease process, and discover novel therapeutic approaches to treat these conditions via the National Cooperative Drug Discovery Group mechanism and screening programs. These therapies are directed at a wide variety of infectious diseases including those produced by HIV, cytomegalovirus, Herpes simplex, Pneumocystis pneumonia, Candida albicans, Mycobacterium avium complex, etc. Some but not all of the NIAID funded drug discovery mechanisms have the capability and capacity to carry out the required studies to convert chemicals exhibiting activity in a predictive in vitro test system or animal model into a pharmaceutical dosage form manufactured on sufficient scale to permit phase I and II clinical evaluation of the substance. This initiative provides analytical chemistry/quality control capability to verify the identity and assess the purity of the chemicals prior to evaluation in: in vivo animal models, toxicology studies, pharmaceutical dosage forms, and clinical trials. In addition, the contractor will evaluate the solubility and stability of these agent and recommend procedures for the appropriate handling of these compounds during evaluation in vivo models of efficacy and toxicity. Determinations of partition coefficients, pKa's, and Ph versus stability profiles, will be used to obtain preliminary information on a new compound that may predict for biologic behavior. The contractor will also assay the final dosage form and assess its stability over time. Methodology to estimate the drug in blood and urine also will be developed.